BioCryst director granted stock, options in Form 4

BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported equity compensation awards rather than open-market trades.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported equity compensation awards rather than open-market trades. He received 15,294 shares of Common Stock as a grant, increasing his directly held stake to 108,483 shares. These were granted at no cash purchase price as part of his director compensation.

Milano was also granted an Automatic Stock Option for 33,540 shares of Common Stock with a conversion or exercise price of $8.50 per share. According to the company’s Non-Employee Director Compensation Policy, the Restricted Stock Units vest on the first anniversary of the grant date, and the stock options expire in 2036, reflecting routine, policy-based director compensation.

Insider Trade Summary

Grant/Award: 48,834 shares

Grant/Award 2 txns

Insider MILANO VINCENT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 contracts (Direct); Common Stock — 108,483 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

Common Stock grant: 15,294 shares Shares held after grant: 108,483 shares Stock option grant size: 33,540 options +2 more

5 metrics

Common Stock grant 15,294 shares Non-derivative equity award to director on June 11, 2026

Shares held after grant 108,483 shares Total Common Stock directly owned following award

Stock option grant size 33,540 options Automatic Stock Option Grant to purchase Common Stock

Option exercise price $8.50 per share Conversion or exercise price for option grant

Option expiration 2036-06-11 Expiration date of Automatic Stock Option Grant

Key Terms

Restricted Stock Units, Automatic Stock Option Grant, Non-Employee Director Compensation Policy, exercise price

4 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Automatic Stock Option Grant financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."

Non-Employee Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy")"

exercise price financial

"conversion or exercise price of 8.5000 for the Automatic Stock Option Grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BCRX director Vincent Milano report in this Form 4 filing?

Vincent Milano reported receiving equity compensation awards, not market trades. He was granted 15,294 shares of Common Stock and an option for 33,540 shares as part of BioCryst’s non-employee director compensation program, increasing his direct ownership stake.

How many BCRX shares does Vincent Milano hold after these grants?

After the Common Stock grant, Vincent Milano directly holds 108,483 shares. This figure reflects his ownership following the award of 15,294 shares under the company’s director compensation policy and indicates a higher long-term equity stake in BioCryst.

What are the terms of Vincent Milano’s new BCRX stock option grant?

Milano received an Automatic Stock Option for 33,540 shares of Common Stock with an exercise price of $8.50 per share. The option was granted under BioCryst’s Non-Employee Director Compensation Policy and expires in 2036, providing a long-dated equity incentive.

When do Vincent Milano’s newly granted BCRX Restricted Stock Units vest?

The Restricted Stock Units granted to Vincent Milano will vest on the first anniversary of the grant date. This one-year vesting period is specified in the Non-Employee Director Compensation Policy and encourages continued board service before shares fully vest.

Are Vincent Milano’s BCRX Form 4 transactions open-market buys or sells?

They are not open-market buys or sells. The transactions are coded as “A” for grant, award, or other acquisition, reflecting equity compensation awards under the director compensation policy rather than discretionary purchases or sales in the public market.

What policy governs Vincent Milano’s BCRX director equity awards?

His equity awards are governed by the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended. This policy provides for automatic grants of Restricted Stock Units and stock options to non-employee directors, with specified vesting and option terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILANO VINCENT

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	108,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)